Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6FX2G
|
|||
| Drug Name |
VIC-1911
|
|||
| Synonyms |
TAS 119
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
VITRAC Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora kinase A (AURKA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Oocyte meiosis | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling by Aurora kinases | ||||
| Integrin-linked kinase signaling | ||||
| PLK1 signaling events | ||||
| Aurora A signaling | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Regulation of PLK1 Activity at G2/M Transition | ||||
| WikiPathways | EGF/EGFR Signaling Pathway | |||
| JAK/STAT | ||||
| Gastric Cancer Network 1 | ||||
| Integrated Breast Cancer Pathway | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of VITRAC Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.